published meta-analysis   sensitivity analysis   studies

azithromycin in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44] 0.43[0.13; 1.44]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable clinical improvementdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] 0.82[0.47; 1.43]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable clinical improvement (14-day)detailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] 0.82[0.47; 1.43]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable clinical improvement (7-day)detailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35] 0.89[0.59; 1.35]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable mechanical ventilationdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37] 1.54[0.70; 3.37]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable radiologic improvement (14-day)detailed resultsRashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88] 1.64[0.94; 2.88]Rashad A (AZI vs SoC), 202110%206NAnot evaluable serious adverse eventsdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10] 1.02[0.20; 5.10]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%438NAnot evaluable adverse eventsdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78] 1.21[0.82; 1.78]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%438NAnot evaluable renal impairmentdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86] 1.35[0.47; 3.86]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-03-29 15:36 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 619 - roots T: 290